Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase I trial results presented for perillyl alcohol

June 19, 1998

Introgen reports results of phase I/II adenoviral-p53 gene therapy trial

June 19, 1998

biosyn Arzneimittel seeks licensees for its oncolytic products

June 19, 1998

Second trial begins for DTI-136 in the treatment of liver cancer

June 18, 1998

Abarelix poised to enter phase III clinical development

June 18, 1998

Irish research organization discovers MAO inhibitor with cytoprotective effects

June 18, 1998

Oncolym makes progress in phase II

June 18, 1998

P&U identifies potent distamycin derivatives with improved therapeutic indices

June 18, 1998

New dihydrofolate reductase inhibitors with antitumor and antiparasitic activities

June 17, 1998

Yissum discloses peptidomimetic protein farnesyltransferase inhibitors

June 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.